Place your pharma strategy bets: focused or cheap?
This article was originally published in Scrip
Executive Summary
For a pharma company, tax inversion has been such a painless way to make money go further that the theme has somewhat obscured the other motives for industry deal-making. However, with the US Treasury's abrupt tightening of the reins on 22 September (scripintelligence.com, 23 September 2014), it may be time to take a step back and consider what those other drivers might be.